뒤로
RAPT Therapeutics Inc (RAPT) 수입
RAPT 주가 차트
RAPT 수입
RAPT Therapeutics Inc
$58.02
0%
$0
종가: Mar 20, 16:00:00 GMT-4
$58.02
0%
$0
애프터마켓: Mar 20, 20:00:00 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-06
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
RAPT의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
RAPT Therapeutics Inc RAPT의 지난 분기 매출 실적은 어땠나요?
RAPT Therapeutics Inc의 매출 추정치는 얼마인가요?
RAPT Therapeutics Inc의 수익 품질 점수는 얼마인가요?
RAPT Therapeutics Inc는 언제 수익을 보고하나요?
RAPT Therapeutics Inc의 예상 수익은 얼마인가요?
RAPT Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$58.02
시가
$57.98
일일 범위
$57.98 - $58.02
52주 범위
$5.66 - $58.02
거래량
11.0M
평균 거래량
2.4M
EPS(TTM)
-11.77
배당수익률
--
시가총액
$1.6B
RAPT란 무엇인가요?
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.